Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARDs (bDMARDs) and other novel DMARDs for second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergrath, Evelien, Gerber, Robert A., Gruben, David, Lukic, Tatjana, Makin, Charles, Wallenstein, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362710/
https://www.ncbi.nlm.nih.gov/pubmed/28377787
http://dx.doi.org/10.1155/2017/8417249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362710/
https://www.ncbi.nlm.nih.gov/pubmed/28377787
http://dx.doi.org/10.1155/2017/8417249

Ejemplares similares